메뉴 건너뛰기




Volumn 28, Issue SUPPL. 4, 2011, Pages 6-11

Azacitidine adverse effects in patients with myelodysplastic syndromes

Author keywords

azacitidine; azacitidine side effects; hematological toxicity; myelodysplastic syndromes; myelosuppression

Indexed keywords

ANTIBIOTIC AGENT; AZACITIDINE; BENZODIAZEPINE DERIVATIVE; CORTICOSTEROID; DEXCHLORPHENIRAMINE; DIURETIC AGENT; ENALAPRIL; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; ONDANSETRON; ORAL ANTIDIABETIC AGENT; RECOMBINANT ERYTHROPOIETIN; VITAMIN;

EID: 79959586688     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0024-2     Document Type: Article
Times cited : (15)

References (8)
  • 2
    • 62849104641 scopus 로고    scopus 로고
    • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study
    • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223-232.
    • (2009) Lancet Oncol , vol.10 , pp. 223-232
    • Fenaux, P.1    Mufti, G.J.2    Hellstrom-Lindberg, E.3
  • 3
    • 84868338638 scopus 로고    scopus 로고
    • Available at: Accessed December 3, 2010
    • Vidaza® [drug brochure]. Available at: http://www.emea.europa.eu/ docs/es-ES/document-library/EPAR---Product-Information/human/000978/WC500050239. pdf. Accessed December 3, 2010.
    • Vidaza® [Drug Brochure]
  • 4
    • 69249108154 scopus 로고    scopus 로고
    • The effects of continued azacitidine (AZA) treatment cycles on response in higher-risk patients with myelodysplastic syndromes
    • (ASH Annual Meeting Abstracts). Abstract 227
    • Silverman LR, Fenaux P, Mufti G, et al. The effects of continued azacitidine (AZA) treatment cycles on response in higher-risk patients with myelodysplastic syndromes. Blood (ASH Annual Meeting Abstracts). 2008;112. Abstract 227.
    • (2008) Blood , vol.112
    • Silverman, L.R.1    Fenaux, P.2    Mufti, G.3
  • 5
    • 77954753267 scopus 로고    scopus 로고
    • Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine
    • Santini V, Fenaux P, Mufti GJ, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol. 2010;85:130-138.
    • (2010) Eur J Haematol , vol.85 , pp. 130-138
    • Santini, V.1    Fenaux, P.2    Mufti, G.J.3
  • 6
    • 77957018936 scopus 로고    scopus 로고
    • Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion
    • Fenaux P, Bowen D, Gattermann N, et al. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. Leuk Res. 2010;34:1410-1416.
    • (2010) Leuk Res , vol.34 , pp. 1410-1416
    • Fenaux, P.1    Bowen, D.2    Gattermann, N.3
  • 7
    • 77955902058 scopus 로고    scopus 로고
    • Feasibility of therapy with hypomethylating agents in patients with renal insufficiency
    • Batty GN, Kantarjian H, Issa JP, et al. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk. 2010;10:205-210.
    • (2010) Clin Lymphoma Myeloma Leuk , vol.10 , pp. 205-210
    • Batty, G.N.1    Kantarjian, H.2    Issa, J.P.3
  • 8
    • 77649296804 scopus 로고    scopus 로고
    • Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil
    • Platzbecker U, Aul C, Ehninger G, Giagounidis A. Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil. Ann Hematol. 2010;89:427-428.
    • (2010) Ann Hematol , vol.89 , pp. 427-428
    • Platzbecker, U.1    Aul, C.2    Ehninger, G.3    Giagounidis, A.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.